Status:
RECRUITING
Immune Checkpoint Inhibitors Nephrotoxicity
Lead Sponsor:
R. Laura Vicente Vicente
Collaborating Sponsors:
Instituto de Investigación Biomédica de Salamanca
Hospital Clínico Universitario de Valladolid
Conditions:
Kidney Injury
Antineoplastics Toxicity
Eligibility:
All Genders
18-100 years
Brief Summary
In recent years, immunotherapy has been postulated as one of the most effective strategy in the fight against cancer. The greatest success in this field has been achieved through the inhibition of mol...
Detailed Description
During the last decade, advances in the knowledge of both the immune response to tumors, as well as the understanding of their evasion mechanisms, has made it possible to design treatments aimed at im...
Eligibility Criteria
Inclusion
- Patients waiting for immunotherapy or combination immunotherapy / platinum compounds
Exclusion
- Patients who are terminally ill
- Patients who do not wish to sign the informed consent
Key Trial Info
Start Date :
May 19 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2030
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT04902846
Start Date
May 19 2021
End Date
December 30 2030
Last Update
February 26 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Servicio de Oncología del CAUSA
Salamanca, Spain
2
Servicio de oncología del Hospital Universitario de Valladolid
Valladolid, Spain